| |
| |
|
| Insider
Information: |
Katkin Keith |
| Relationship: |
Director |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
1,258,490 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$4,748,657 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
1,258,490 |
|
|
| Total
Value |
$4,748,657 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Avanir Pharmaceuticals |
AVNR |
President and CEO, Dir... |
2014-12-17 |
914,249 |
2006-05-25 |
0 |
Premium* |
|
|
Eledon Pharmaceuticals Ord Shs |
ELDN |
Director |
2017-05-10 |
12,119 |
|
0 |
Premium* |
|
|
Urovant Sciences Ltd. |
UROV |
PEO;CEO/Urovant Scienc... |
2020-02-19 |
199,680 |
2019-12-09 |
0 |
Premium* |
|
|
Syndax Pharmaceuticals Inc |
SNDX |
|
2024-02-07 |
65,000 |
2021-02-03 |
0 |
Premium* |
|
|
Rigel Pharmaceuticals Inc |
RIGL |
Director |
2021-05-19 |
25,000 |
2021-05-19 |
0 |
Premium* |
|
|
Emergent Biosolutions Inc. |
EBS |
Director |
2023-05-25 |
42,442 |
2022-04-02 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SNDX |
Syndax Pharmaceuticals In... |
|
– • – |
2024-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
17,000 |
65,000 |
0 |
- |
|
| EBS |
Emergent Biosolutions Inc... |
Director |
– • – |
2023-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
33,847 |
42,442 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
|
– • – |
2023-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
48,000 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
|
– • – |
2022-10-06 |
4 |
AS |
$25.90 |
$774,411 |
D/D |
(29,899) |
32,000 |
0 |
% |
|
| SNDX |
Syndax Pharmaceuticals In... |
|
– • – |
2022-10-06 |
4 |
OE |
$7.88 |
$245,177 |
D/D |
29,899 |
41,117 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
|
– • – |
2022-10-04 |
4 |
OE |
$7.88 |
$3,071 |
D/D |
360 |
32,223 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
|
– • – |
2022-10-04 |
4 |
AS |
$25.00 |
$9,000 |
D/D |
(360) |
32,000 |
0 |
% |
|
| SNDX |
Syndax Pharmaceuticals In... |
|
– • – |
2022-10-03 |
4 |
AS |
$25.00 |
$4,500 |
D/D |
(180) |
32,000 |
0 |
% |
|
| SNDX |
Syndax Pharmaceuticals In... |
|
– • – |
2022-10-03 |
4 |
OE |
$7.88 |
$1,432 |
D/D |
180 |
32,013 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
|
– • – |
2022-09-30 |
4 |
OE |
$7.88 |
$28,740 |
D/D |
3,561 |
32,647 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
|
– • – |
2022-09-30 |
4 |
AS |
$25.07 |
$89,277 |
D/D |
(3,561) |
32,000 |
0 |
% |
|
| EBS |
Emergent Biosolutions Inc... |
Director |
– • – |
2022-04-02 |
4 |
A |
$0.00 |
$0 |
D/D |
8,595 |
8,595 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
|
– • – |
2022-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
32,000 |
0 |
- |
|
| RIGL |
Rigel Pharmaceuticals Inc |
Director |
– • – |
2021-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
25,000 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
|
– • – |
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
16,000 |
0 |
- |
|
| UROV |
Urovant Sciences Ltd. |
PEO;CEO/Urovant Sciences, Inc. |
• • – |
2020-02-19 |
4 |
D |
$13.08 |
$983,773 |
D/D |
(75,212) |
199,680 |
0 |
- |
|
| UROV |
Urovant Sciences Ltd. |
PEO;CEO/Urovant Sciences, Inc. |
• • – |
2020-02-19 |
4 |
D |
$13.08 |
$1,370,627 |
D/D |
(104,788) |
274,892 |
0 |
- |
|
| UROV |
Urovant Sciences Ltd. |
PEO;CEO/Urovant Sciences, Inc. |
• • – |
2020-02-19 |
4 |
OE |
$3.86 |
$694,800 |
D/D |
180,000 |
379,680 |
0 |
- |
|
| UROV |
Urovant Sciences Ltd. |
PEO;CEO/Urovant Sciences, Inc. |
• • – |
2020-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
199,680 |
199,680 |
0 |
- |
|
| UROV |
Urovant Sciences Ltd. |
PEO;CEO/Urovant Sciences, Inc. |
• • – |
2019-12-09 |
4 |
OE |
$3.86 |
$463,200 |
D/D |
120,000 |
120,000 |
0 |
- |
|
| UROV |
Urovant Sciences Ltd. |
PEO;CEO/Urovant Sciences, Inc. |
• • – |
2019-12-09 |
4 |
AS |
$12.78 |
$1,533,600 |
D/D |
(120,000) |
0 |
0 |
- |
|
| ELDN |
Eledon Pharmaceuticals Or... |
Director |
– • – |
2017-05-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
12,119 |
|
- |
|
| AVNR |
Avanir Pharmaceuticals |
President and CEO |
• • – |
2014-12-17 |
4 |
AS |
$16.93 |
$1,058,464 |
D/D |
(62,520) |
914,249 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
President and CEO |
• • – |
2014-12-15 |
4 |
AS |
$16.95 |
$3,646,962 |
D/D |
(215,160) |
976,769 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
President and CEO |
• • – |
2014-12-15 |
4 |
OE |
$1.29 |
$314,396 |
D/D |
195,160 |
1,171,929 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
